New research has debunked the idea that there is an “obesity paradox”, whereby patients with heart failure who are overweight or obese are thought to be less likely to end up in hospital or die than people of normal weight.The new study – published i
An analysis of data from patients in the DELIVER and DAPA-HF trials in the Americas provides an overview of the benefits of dapagliflozin in Black patients relative to White patients.
Study shows ‘obesity paradox’ does not exist: waist-to-height ratio is a better indicator of outcomes in patients with heart failure than BMI. New research has debunked the idea that there is an “obesity paradox,” whereby patients with heart failure who are overweight or obese are thought to be l